Vical Incorporated (Vical) is a biopharmaceutical company which is principally engaged in the research and development of biopharmaceutical products based on its patented DNA delivery technologies. The company also develops certain infectious disease vaccines and cancer therapeutics. Vical also provides products which consist of plasmid DNA constructs for non commercial applications and cationic lipids. Vical has manufacturing facilities which uses patented purification approaches to manufacture naked DNA plasmids in gram quantities. The company also pursues contract manufacturing opportunities to leverage its manufacturing facilities which is situated in California.
Vical Incorporated (VICL) Key Recent Developments
Aug 03, 2010 Vical Reports Net Loss Of $8.4 Million For Q2 2010
May 25, 2010 Vical Collaborators Receive Grant To Pursue New CMV Vaccine Strategies
May 06, 2010 Vical Reports Total Revenues Of $1.5 Million In Q1 2010
Apr 22, 2010 Vical Secures Funding To Proceed With Phase I Trial Of H1N1 Pandemic Influenza Vaccine
Apr 22, 2010 Vical Releases Positive Preliminary Data From TransVax CMV Vaccine Phase 2 trial
This comprehensive SWOT profile of Vical Incorporated (VICL) provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including,
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company h